Navigation Links
Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Date:5/31/2013

LONDON, May 31, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Bellus Health (TSX: BLU), a Canadian pharmaceutical company developing drugs for amyloid-related diseases.

Edison has recently published a comprehensive report examining the investment merits of Bellus Health, focusing on the company's lead programme, Kiacta, currently in a pivotal Phase III trial for amyloid A (AA) amyloidosis, an orphan drug indication affecting up to 50,000 patients worldwide. In the report, Pivotal play in rare kidney disease, Edison's Canadian-based healthcare analyst, Pooya Hemami , argues that Bellus' investment case is underpinned by Kiacta's 60% probability of success in the pivotal study (based on positive trends in a previous Phase II/III study), the potential for premium pricing and a seven- to-10-year orphan drug market exclusivity period. With the Kiacta trial results not expected until 2017, a long-term view is required, but importantly, Bellus is fully funded until the data read out. Based on a risk-adjusted NPV analysis, Edison values Bellus at C$31m, or C$0.74 per share (fully diluted).

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

For the full report see: http://www.edisoninvestmentresearch.com/research/company/bellus-health

The launch of coverage on Bellus Health is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered i
'/>"/>

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
2. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
3. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
4. Edison Pharmaceuticals Closes $20M Series F Financing
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
7. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
8. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
9. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
10. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
11. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... - NEOPHARM, Inc.,(Nasdaq: NEOL) today reported findings ... metastatic colorectal cancer patients with its,drug product ... While the interim analysis of data following ... patients demonstrated,disease stabilization, the study did not ...
... Science Closer to Targeted, Improved Therapies , BETHESDA, Md., ... Abuse (NIDA), part of the National,Institutes of Health, have ... person's ability to abstain from smoking. The,breakthrough research was ... and a team led by Dr. Jed Rose at ...
Cached Medicine Technology:NeoPharm Provides Update on LE-SN38 Program 2NIDA Study Identifies Genes That Might Help Some People Abstain,from Smoking 2NIDA Study Identifies Genes That Might Help Some People Abstain,from Smoking 3
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
(Date:12/25/2014)... December 25, 2014 Plugin creators from ... 5k. A fully customizable business presentation tool made specifically ... the ProFire 5k business tool, users can now display ... CEO of Pixel Film Studios. “ProFire 5k gives users ... to add professionalism to a presentation” , Pixel Film ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... 7, 2009, the Boston District Court dismissed the "Diomed" lawsuit ... a settlement agreement with Dr. Luis Navarro. This patent ... the use of lasers for endovenous ablation. CoolTouch will ... laser sales and accessories that potentially allow vein wall contact ...
... Awareness Month raises visibility of 900 active groups; National Parkinson Foundation ... ... 13, 2009 - For individuals diagnosed with Parkinson,s disease, self-care and ... and support groups provide an important component for this self-care, according ...
... Americas Watchdog and its Homeowners Consumer Center have been ... Toxic Chinese drywall that was first introduced into the ... certain this involves 100,000,s of homeowners, in all US ... toxic Chinese drywall is corroding copper, metal, and most ...
... are less likely to receive recommended chemotherapy and surgery than ... of lessening. That is the conclusion of a new study ... , a peer-reviewed journal of the American Cancer Society. The ... treatments for black patients and to educate them about the ...
... first time used tiny molecules called microRNAs to help turn ... cells are pluripotent, meaning that, like embryonic stem cells, they ... body. , The findings suggest that scientists will soon ... in laboratory experiments to induce pluripotency in adult cells. This ...
... for EpilepsyThe Toll of Epilepsy Has Been Overlooked - and the ... we need more of a cancerlike sensibility around epilepsy," Newsweek ... cover, " The Mystery of Epilepsy" (on newsstands Monday, April ... do not hesitate to invest the search for a cure for ...
Cached Medicine News:Health News:CoolTouch Inc. Settles Diomed Lawsuit, Files Re-examination Request for Cynosure '873 Patent 2Health News:Parkinson's Support Groups Grow Nationwide 2Health News:Americas Watchdog Calls On President Obama To Get Involved With The Toxic Chinese Drywall Disaster--Now 2Health News:Americas Watchdog Calls On President Obama To Get Involved With The Toxic Chinese Drywall Disaster--Now 3Health News:Americas Watchdog Calls On President Obama To Get Involved With The Toxic Chinese Drywall Disaster--Now 4Health News:Racial disparities persist in the treatment of lung cancer 2Health News:UCSF team closer to creating safe embryonic-like stem cells 2Health News:UCSF team closer to creating safe embryonic-like stem cells 3Health News:NEWSWEEK Cover: The Mystery of Epilepsy 2Health News:NEWSWEEK Cover: The Mystery of Epilepsy 3
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Digitoxin in human serum....
For the quantitative in vitro determination of Phenytoin in human serum....
For the quantitative in vitro determination of Phenobarbital in human serum....
Medicine Products: